Advanced Medicine

Novo Nordisk's Stephen Gough explains how pharma can address the cardiovascular risks associated with type 2 diabetes.

How can we effectively manage the treatment of type 1 diabetes?

The gene and cell therapy market is growing, but does it have the CDMO support needed to maintain its upward trajectory?

Introducing the fourth therapeutic class: live biotherapeutics – microorganisms isolated from the human gut with the potential to treat many diseases.

Nominations are now open for The Medicine Maker 2021 Power List.

Can genomic medicine usher in a new era of curative treatments for neurological diseases? Experts from Sangamo give their views.

A breakthrough in transgenic mice opens the door to “Humabodies.”

We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.

What challenges and opportunities do immunotherapy developers face?

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…